Sanmeet Deo

So, and, you know, I want to hope that, and I think this is true, mostly like,

I know people in research and pharma like they're in it to help people.

Sure, they're there to make a profit, but they want people to be helped.

So, you know, I think they have their eyes on it and is my guess.

And we see where this all goes kind of thing.

Yeah.

And there was, of course, again, Spravato.

That was big pharma that brought Spravato to market, which is ketamine, a ketamine analog.

And, you know, that I think was a lot safer because ketamine has already been around for decades.

It's not marketed as a psychedelic.

inside the medical space.

So that was a safer bet.

But that is a sign of pharma went down that road there.

So I think letting the smaller companies do more of the grassroots work of can we get other types of psychedelics to market.

I piggyback on what Will is saying, that we have been fed a lot of information from the medical establishment, again, not with malintention, and also culturally about what mental illness is and what mental health is.

What's depression?

What is this thing?

Depression, anxiety, there's a lot of just stereotypes about this stuff out there.

and it's sort of like well it's i think a lot of people feel like i've inherited this or i it's not a lot i can do about it on some level i have some symptoms i need to get rid of and i would say that uh there are actually known causes having these symptoms are actually signals in your body that you just got to go understand how these signals work to go address the cause and

And once you do that, you get well.